Vaccines Global Market Intelligence Report 2026-2035 Featuring Bio Farma, Emergent BioSolutions, GC Pharma, GlaxoSmithKline, Janssen, Merck, Novavax, Moderna, Pfizer, Sanofi Pasteur, and Valneva
Dublin, Sept. 07, 2026 (GLOBE NEWSWIRE) — The “Vaccines Market Distribution by Type of Vaccine API, Targeted Patient Population, Type of Vaccines, Route of Administration, and Key Geographical Region – Trends and Forecasts Till 2035” has been added to ResearchAndMarkets.com’s offering.
The global vaccines market is projected to increase from approximately USD 48 billion to USD 94 billion by 2030, representing a compound annual growth rate of about 11.9% during the forecast period. Market expansion is being supported by the persistent burden of infectious diseases, broader national immunization programs, advances in vaccine technology and growing investment in regional manufacturing capacity.
Vaccines Market Growth Drivers and Industry Trends
Governments, global health organizations and vaccine manufacturers are strengthening immunization coverage in response to emerging and re-emerging pathogens. Expanded programs targeting diphtheria, pertussis, tetanus, measles, human papillomavirus, influenza, pneumococcal disease, dengue, malaria and respiratory syncytial virus are contributing to sustained global demand.
Multilateral funding and public-private partnerships are also improving vaccine access across low- and middle-income countries. Investments in localized production, including manufacturing partnerships in Africa and other underserved regions, are expected to strengthen supply resilience, reduce import dependence and improve preparedness for future outbreaks.
Technological progress remains a major contributor to vaccines market growth. Recombinant and mRNA vaccine platforms are enabling faster development cycles, multivalent formulations and more agile responses to emerging infectious diseases. At the same time, advances in adjuvants, thermostable formulations, intranasal delivery, oral vaccines and microneedle-based administration are broadening development opportunities and improving accessibility.
Market Challenges and Emerging Opportunities
Specialized manufacturing requirements, high production costs and complex regulatory standards continue to affect capacity expansion. Cold-chain logistics remain a significant barrier in remote and resource-constrained markets, while affordability, uneven healthcare access and vaccine hesitancy can restrict immunization uptake.
These challenges are creating opportunities for manufacturers developing thermostable products, needle-free delivery systems and formulations with less demanding storage requirements. Coordinated public health communication, regional manufacturing investment and accelerated regulatory pathways are also expected to support wider adoption.
Industry investment is increasingly shifting from COVID-19 vaccines toward high-growth infectious disease targets, including RSV, influenza, pneumococcal disease, dengue, malaria, HPV and Lyme disease. Strategic partnerships are focusing on co-development, technology licensing, manufacturing scale-up and regional commercialization. The preventive vaccine pipeline remains highly active, with more than 1,400 completed, ongoing and planned clinical studies across multiple platforms, pathogens and patient populations.
Key Vaccines Market Insights
- mRNA technology is supporting multivalent, combination and rapid-response vaccine development.
- Public-private partnerships are strengthening pandemic preparedness, production capacity and global vaccine accessibility.
- Biotechnology companies, academic institutions and regional manufacturers are increasing competition in a market historically led by multinational pharmaceutical companies.
- Accelerated review pathways and collaborative approval mechanisms are supporting vaccines that address emerging threats and unmet medical needs.
- Current development priorities include RSV portfolios, next-generation influenza products, malaria and dengue vaccines, and universal coronavirus candidates.
- Thermostable, intranasal, oral and microneedle-based vaccines are being advanced to improve access, acceptance and immunization outcomes.
Vaccines Market Segmentation
The report evaluates the market by vaccine API type, targeted patient population, vaccine category, route of administration and geographic region. Vaccine API segments include conjugate, inactivated and subunit, live-attenuated, recombinant and toxoid vaccines. Patient populations are divided into pediatric and adult groups.
Key vaccine categories include pneumococcal conjugate, human papillomavirus, rotavirus, influenza, measles-mumps-rubella, varicella, tetanus and diphtheria booster, DTaP-Hib-IPV and DTaP-HepB-Hib-IPV vaccines. Routes of administration include intramuscular, subcutaneous, oral, intravenous and other delivery methods.
Regional and Segment Outlook
Live-attenuated vaccines are expected to retain a leading market position, supported by established clinical use, recognized regulatory pathways and extensive inclusion in pediatric immunization schedules. Continued improvements in attenuation and stabilization technologies are expected to maintain the segment’s relevance as next-generation platforms gain market share.
North America is projected to remain the largest regional contributor to global vaccines market revenue through 2030. Its leadership is supported by strong public health infrastructure, favorable reimbursement conditions, extensive research activity and rapid adoption of newly approved respiratory and variant-adapted vaccines.
Asia-Pacific is forecast to register the fastest regional growth. Key factors include large target populations, expanding immunization infrastructure, improving healthcare access and coordinated programs that add HPV, typhoid conjugate and other vaccines to routine schedules. Europe and the rest of the world will also benefit from product innovation, broader adult vaccination programs and investment in supply security.
Leading Companies in the Global Vaccines Market
Companies profiled in the competitive assessment include Bio Farma, Emergent BioSolutions, GC Pharma, GlaxoSmithKline, Janssen, Merck, Moderna, Novavax, Pfizer, Sanofi Pasteur and Valneva. The analysis compares participants based on company scale, industry experience, clinical-stage pipelines, development phases, routes of administration and breadth of targeted indications.
Research Coverage
The vaccines market report provides top-down and bottom-up market sizing, segment-level forecasts and opportunity analysis. It reviews marketed and clinical-stage candidates by developer type, development phase, vaccine API, dosage form, dosing regimen, disease indication and patient population.
Additional coverage includes company benchmarking, manufacturer profiles, clinical trial activity, disease-specific development programs, funding and investment trends, and the vaccine contract manufacturing landscape. The report also assesses recent partnerships, approvals, financing rounds and policy developments affecting competition and market access.
Forecasts include base-case, conservative and optimistic scenarios, enabling stakeholders to assess performance under different regulatory, funding and adoption conditions. Findings are supported by primary research involving clinicians, research and development leaders, and senior executives across the vaccine industry.
Strategic Value for Industry Stakeholders
The research is designed to support pharmaceutical companies, biotechnology developers, investors, healthcare organizations and policymakers evaluating the global vaccines market. It provides revenue estimates by vaccine API, patient population, route of administration and geography, alongside competitive benchmarking and investment tracking for use in strategic planning, licensing, due diligence and market-entry decisions.
Purchasers also receive presentation and spreadsheet data packs, access to content customization, an in-depth walkthrough with the research team and a complimentary update when the report is more than six months old.
A selection of companies mentioned in this report includes, but is not limited to:
- Bio Farma
- Emergent BioSolutions
- GC Pharma
- GlaxoSmithKline
- Janssen
- Merck
- Novavax
- Moderna
- Pfizer
- Sanofi Pasteur
- Valneva
For more information about this report visit https://www.researchandmarkets.com/r/gtlvrh
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
CONTACT:
CONTACT: ResearchAndMarkets.com
Laura Wood,Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
